logo
Paras Defence shares fall 6% as post-split rally stalls

Paras Defence shares fall 6% as post-split rally stalls

Time of India5 days ago
Paras Defence and Space Technologies' shares declined 6.1% on Monday due to profit booking after a recent rally triggered by a 1:2 stock split. Despite the dip, the stock remains above key moving averages, indicating underlying strength. However, an overbought RSI suggests a potential near-term pullback, even as the stock has shown strong gains over the past year.
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
Shares of Paras Defence and Space Technologies fell as much as 6.1% on Monday to Rs 876.55 on the BSE , as investors booked profits following last week's sharp rally triggered by the company's 1:2 stock split The stock, which had surged over 8% on Friday post-adjustment, saw a reversal in sentiment even as underlying technical indicators continued to show strength. The decline comes despite bullish cues, with the stock still trading above all eight key simple moving averages (SMAs) — from the 5-day to the 200-day — and the Moving Average Convergence Divergence (MACD) remaining above both the center and signal lines.Friday's rally followed the company's stock split becoming effective on July 4, which was also the record date for the sub-division. The split, changing the face value from Rs 10 to Rs 5 per share, had been approved by shareholders via postal ballot on June 7, 2025, as disclosed in a regulatory filing under SEBI's Listing Obligations and Disclosure Requirements (Regulation 42).However, with the Relative Strength Index (RSI) at 70.7 — a level considered overbought — a near-term pullback remains likely. Paras Defence shares continue to show strong performance over broader timeframes. The stock is up 14.4% over the past year and has surged 82.4% in the last six months. In the past three months alone, it has gained 79%, including a 7% rise over the past month. Paras Defence 's market capitalisation currently stands at Rs 7,442.64 crore.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RVNL bags LoA for OHE upgradation project from
RVNL bags LoA for OHE upgradation project from

Business Standard

time29 minutes ago

  • Business Standard

RVNL bags LoA for OHE upgradation project from

Rail Vikas Nigam (RVNL) has been awarded a letter of acceptance (LoA) by the South Central Railway for a significant project valued at Rs 213.22 crore. The contract encompasses the design, supply, erection, testing, and commissioning of an overhead equipment (OHE) upgradation project. This involves converting the existing 1x25kV system to a 2x25kV feeding system, including associated feeder and earthing works. The scope of work covers the Duvvada-Rajahmundry and Samalkot-Kakinada Port sections of the Vijayawada Division, falling under South Central Railway. The total length of the project spans 195.5 track kilometers (RKM) / 391 equivalent track kilometers (TKM). The domestic contract has to be executed within a period of 24 months. Rail Vikas Nigam is in the business of executing all types of railway projects, including new lines, doubling, gauge conversion, railway electrification, metro projects, workshops, major bridges, construction of cable-stayed bridges, institution buildings, etc. The company reported a 4.05% decrease in consolidated net profit to Rs 459.15 crore in Q4 FY25 as against Rs 478.56 crore posted in Q4 FY24. Revenue from operations slipped 4.27% YoY to Rs 6,426.88 crore in the quarter ended 31 March 2025. The scrip shed 0.81% to end at Rs 381.55 on the BSE on Friday.

Gland Pharma gets GMP certificate for Telangana-based facility from Danish Medicines Agency
Gland Pharma gets GMP certificate for Telangana-based facility from Danish Medicines Agency

Business Standard

time29 minutes ago

  • Business Standard

Gland Pharma gets GMP certificate for Telangana-based facility from Danish Medicines Agency

Gland Pharma said that its Pashamylaram facility has received certificate of good manufacturing practices (GMP) compliance from Danish Medicines Agency. Pashamylaram is a village located in Patancheru mandal of Medak district in Telangana, India. This certification specifically covers the facility's production of aseptically prepared powder for injection, infusion, and inhalation. This GMP certificate is crucial for Gland Pharma as it pertains to marketing authorizations that list manufacturers located outside of the European Economic Area (EEA), allowing their products to be marketed within Denmark and potentially other EEA countries. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered heparin technology in India. The company's consolidated net profit declined 3.06% to Rs 186.54 crore as net sales fell by 7.32% to Rs 1424.91 crore in Q4 FY25 as compared with Q4 FY24. The scrip had gained 0.89% to end at Rs 1859.05 on the BSE on Friday.

Order win: Over 500% returns in 5 years! Construction company secures LoA for Mumbai Metro project
Order win: Over 500% returns in 5 years! Construction company secures LoA for Mumbai Metro project

Indian Express

time2 hours ago

  • Indian Express

Order win: Over 500% returns in 5 years! Construction company secures LoA for Mumbai Metro project

NCC Share Price: Shares of NCC Limited closed in red on Friday (July 11). The construction stock settled at Rs 220.85 apiece, down 1.19 per cent. According to the NSE, the total market cap of NCC Limited is Rs 13865.99 crore. The stock registered a 52-week-high of Rs 364.50 on July 31, 2024. It recorded 52-week-low of Rs 170.05 on March 3, 2025. In a regulatory filing on July 11, NCC Limited said that it has received a Letter of Acceptance (LoA) from MMRDA for Mumbai Metro Line 6 – Package 1-CA-232. The contract value is Rs 2269 crore approx (excluding GST). NCC Limited will be responsible for 'Design, Manufacture, Supply, Installation, Integration, Testing, and Commissioning of Rolling Stock, Communication-Based Signaling & Train Control, Telecommunication Systems, Platform Screen Doors and Depot Machinery & Plant for Line 6 [Swami Samarth Nagar to Vikhroli – (EEH)] of the Mumbai Metro Rail Project,' it said in an exchange filing. NCC Limited is a component of BSE 500. According to the BSE analytics (as of July 12), shares of NCC Limited gave negative returns of 1.42 per cent and 3.48 per cent in the last 1 week and 2 weeks, respectively. Shares of the company also fell in the last 1 year by 33.33 per cent. However, in the past 2 years, 3 years, 5 years and 10 years, shares of the civil construction company gained 74.13 per cent, 279.06 per cent, 561.94 per cent, and 177.53 per cent, respectively. In 2023 and 2024, NCC Ltd paid dividends of Rs 2.20 each. In 2022, the company paid a dividend of Rs 2. In 2020 and 2021, the company announced dividends of Re 0.20 and 0.80, respectively. NCC Limited never issued bonuses for the equity shareholders.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store